U
STML

UBS’s Stemline Therapeutics, Inc. STML Stock Holding History

UBS’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$29K Sell
2,350
-631
-21% -$7.77K ﹤0.01% 7516
2014
Q2 		$43K Buy
2,981
+909
+44% +$13.9K ﹤0.01% 7076
2014
Q1 		$43K Buy
2,072
+1,038
+100% +$25.2K ﹤0.01% 7051
2013
Q4 		$20K Buy
1,034
+1,009
+4,036% +$26.9K ﹤0.01% 8167
2013
Q3 		$1K Buy
+25
New +$815 ﹤0.01% 10195

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

UBS's STML Position: Q3 2014 in Review

UBS reduced its Stemline Therapeutics, Inc. (STML) stake by 21% in Q3 2014, selling an estimated $7.77K and leaving 2,350 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #7516.

UBS first reported a position in STML in Q3 2013 and has held it in 5 quarters since. The position peaked at $43K in Q2 2014. 61 funds tracked by Wall St. Rank hold STML as of Q3 2014.

  • UBS held 2,350 shares of Stemline Therapeutics, Inc. worth $29K as of Q3 2014.
  • UBS sold 631 Stemline Therapeutics, Inc. shares in Q3 2014, an estimated $7.77K.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7516 holding.
  • UBS first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and has held it in 5 quarters since.
  • UBS's Stemline Therapeutics, Inc. position peaked at $43K in Q2 2014.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.